Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab plus azacitidine versus physician's choice therapy in previously untreated TP53-mutant acute myeloid leukemia
2020-003949-11Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of magrolimab in acute myeloid leukemia (AML) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Overall Survival in the Stratum of Patients Appropriate for Non-intensive Therapy. Started Jun 2021; status: completed.
02
Drugs
magrolimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2020-003949-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003949-11.